核因子受体激活因子-κB配体 (receptor activator for nuclear factor-κB ligand，RANKL)是由位于人染色体13q14上的基因Tnfsf11编码的可溶性蛋白，存在于OBs、T淋巴细胞、B淋巴细胞及骨 …

2012年12月14日 · These results demonstrate that reduction of CXCL16–CXCR6 is critical in RANKL-mediated osteoclastogenesis, which is mainly through the activation of JAK2/STAT3 …

2022年10月1日 · Studies have shown that cytokines mainly promote the formation of OCs and play a role in bone resorption by stimulating OBs to express receptor activator of NF-κB ligand …

2017年7月14日 · Baricitinib suppressed 1,25D3 and PGE2-induced up-regulation of RANKL in osteoblasts, but not macrophage colony-stimulating factor expression. Moreover, the addition …

核因子-κB配体（RANKL）的受体激活剂是肿瘤坏死因子（TNF）家族的成员，在破骨细胞的分化和功能中起着至关重要的作用。 最近已显示趋化因子及其受体在破骨细胞形成中起关键作 …

2013年2月13日 · This study investigated whether the calcineurin inhibitor, tacrolimus, suppresses receptor activator of NF-κB ligand (RANKL) expression in fibroblast-like synoviocytes (FLS) …

In the current study, we demonstrate that a selective Jak1 and Jak2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts induced by 1,25D 3 and …

Studies have shown that cytokines mainly promote the formation of OCs and play a role in bone resorption by stimulating OBs to express receptor activator of NF-κB ligand (RANKL). …

This study was undertaken to investigate how selective inhibition of JAK with tofacitinib (CP-690,550) affects osteoclast-mediated bone resorption in a rat adjuvant-induced arthritis (AIA) …

目的 探讨JAK2/SATA3信号通路对核因子kB受体活化因子配体 (Receptor activator of NF-κB Ligand,RANKL)诱导RAW264.7细胞向破骨细胞分化过程的影响.方法 用ATP竞争性JAK2激酶 …